To obtain the subject new antibody capable of binding to human monocyte chemotactic activation factor (human MCP-1) and suppressing action of MCP-1, free from adverse effect and useful for treating and preventing diseases accompanying inflammation, e.g. idiopathic pulmonary fibrosis, glomerulonephritis and arterial sclerosis.
This monoclonal antibody is bound to human monocyte chemotactic activation factor (human MCP-1). The antibody binds to MCP-1 concerning accentuation and activation of chemotaxis of monocyte and macrophage and suppresses its action and is useful as a treating and preventing agent, etc., of diseases accompanying inflammation reaction in which monocyte and macrophage participates, e.g. idiopathic pulmonary fibrosis, glomerulonephritis and arterial sclerosis. The monoclonal antibody is obtained by separating blood cells by Ficoll separating liquid from peripheral blood of a normal subject to provide a human mononucleosis fraction, then infecting the fraction with Epstein-Barr virus(EBV) and culturing the fraction and selecting human MCP-1 antibody-producing monocyte from the cultured products and fusing the monocyte with a myeloma cell, culturing the fused cell, selecting a strain which forms colony and culturing the strain.
| JP2003055399 | ANTI-PLASMA MEMBRANE SIALIDASE MONOCLONAL ANTIBODY |
| WO/1998/017797 | ANTI-ErbB2 ANTIBODIES |
| JP4052524 | Ligand for inducing antigen-specific apoptosis in T cells |
TAKAGI SHIRO
MITA IZUMI
SATOZAWA NOBORU
WATANABE AYAKO
YOKOMATSU TOMOKO
